A shadow market for unlicensed weight-loss medications is being driven by social media fitness personalities and vendors on messaging platforms, based on new investigations.
Investigational Drug Gaining Traction Online
The experimental drug, which remains in research studies, is being promoted by social media influencers for its supposed fat-burning effects. Followers are encouraged to contact these profiles privately for source information, while also obtaining promotional offers.
Thriving Commerce on Social Networks
Separately, a robust market exists on messaging services, where groups with numerous of members share comparison photos, injection guides and claims of next-day British shipping. Sellers promote the drug there before redirecting buyers to other platforms for transactions.
Learning About Retatrutide
Retatrutide is an investigational injectable developed by American pharmaceutical company Eli Lilly. The drug targets three intestinal hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Preliminary studies indicate it could help patients lose up to a quarter of their total weight. Nicknamed the “triple G”, the drug is being promoted online as the next Ozempic.
Medical Professionals Voice Concerns
Nevertheless, physicians and pharmacists have cautions that the sale of what is still an unlicensed medication in the United Kingdom is a cause for concern and could lead to users administering products of uncertain source.
Several professionals stated the popularity for retatrutide could be connected to the rising price of licensed slimming treatments such as Mounjaro.
Legal Status and Enforcement
Selling the unapproved drug on social media or messaging apps is illegal in the United Kingdom, as it is an unlicensed drug that cannot be marketed or supplied for personal consumption under the Human Medicines Regulations 2012.
Several influencers attempt to sidestep the rules by calling to the drug as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a controlled substance, but advertising and distribution can still violate pharmaceutical, advertising, and consumer regulations, risking penalties, legal action or imprisonment.
Service Reaction and Content Elimination
Based on TikTok, the service has taken down problematic material and banned related keywords and query recommendations. The organization said it was committed to maintaining the platform secure and investing in strengthening compliance measures.
Online Trading Activities
Research also discovered groups with up to 9,000 participants selling retatrutide using Telegram's integrated search feature, which operates like a online catalog. Typing “retatrutide” immediately brings up groups with numerous of members, populated with images of slimming results, positive testimonials and step-by-step guides for preparing or administering at residence.
Within moments of entering one community, a seller posted WhatsApp details, where most purchases occur. The vendor provided an instruction manual and promised delivery within 48 hours. When questioned whether the product was authentic, one seller said: “You can’t be sure.” Another shared a image of a supposed laboratory certificate. None inquired about weight, medical conditions or previous experience.
Item Information and Costs
Within these groups, posts display black plastic packages with Royal Mail labels, claiming to include fresh supplies. One message stated: “It took eight of us to load them this morning.”
Customers can select between powder vials, mixed at residence with purified liquid, or ready-to-use injectors usually priced at £160 for 20mg. When asked how long a pen should last, vendors give conflicting responses varying between a few weeks to “depends on your body”.
Platform Moderation and Security Measures
A spokesperson for the messaging service said it actively monitored dangerous material on its platform including material that promoted the “misuse of controlled medications”. The organization added that it removed “millions of pieces of harmful content each day”.
Medical Professional Warnings
“Individuals are injecting materials they cannot confirm. Although the research behind retatrutide is sound, these digital products may not contain what they advertise,” said a pharmacy expert, the director of pharmaceutical services at a pharmacy service.
Dr Crystal Wyllie of an online medical service linked the surge in demand to recent cost increases for approved slimming drugs such as Mounjaro. “With costs rising, individuals are using social media. But fake injections are highly risky. You can’t be certain what’s contained or whether the conditions they were made in was sterile,” she explained.
Her staff has previously encountered individuals harmed by personal administration from unconfirmed suppliers. “We recognize the disappointment, but purchasing from messaging apps or WhatsApp is taking chances with your well-being,” said the doctor. “These materials could be impure or improperly measured.”
Producer Statement
A spokesperson from Eli Lilly stated the substance was in phase 3 research studies and had not been reviewed or approved by any government authority anywhere in the world. “Consequently at this point no one can market [it] for human use,” they said, noting that any product “misleadingly claiming itself as a Lilly investigational substance not yet approved … may expose patients to possibly significant health risks”.
